Search the Newsreel

Central Puerto SA Sponsored ADR Financial Disclosures & SEC Filings

This page provides access to Central Puerto S.A. (CEPU) financial disclosures and SEC filings, including Forms 10-K, 10-Q, 8-K, and annual reports. Users can explore earnings call transcripts, earnings releases, and presentation slides to evaluate the company's financial performance and operational updates. The documents …

Central Puerto Q2 Earnings Call Highlights

Key Points Interested in Central Puerto S.A. Sponsored ADR? Here are five stocks we like better. Second-quarter results surged: Adjusted EBITDA rose 136.2% year over year to $145.0 million, while revenue increased 165.8% to $453.3 million, supported by higher contracted sales, seasonal spot pricing …

Earnings call transcript: Central Puerto posts strong Q2 2026 growth, stock rises

Central Puerto reported a significant increase in Q2 2026 revenue and adjusted EBITDA, driven by strong contracted sales and increased spot-market activity. The company's revenue reached $453.3 million, up 165.8% year-over-year, with adjusted EBITDA climbing to $145.0 million. Key takeaways include a 35% MAT …

Concentra Group Holdings Parent (CON) Following Earnings And Guidance Lift Through A Valuation Lens

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Concentra Group Holdings Parent (CON) has given investors a cluster of fresh information in August 2026, including second quarter earnings, new full year …

Central Puerto (NYSE: CEPU) boosts H1 2026 earnings and expands hydro assets

Central China Securities Backs New Henan Digital Tourism Investment Partnership

Central Puerto Posts Strong First-Half 2026 Earnings and Bolsters Asset Base

Entravision Communications: Wild After Hours Trading Obscures Progress (NYSE:EVC)

NTRA Maintained by Guggenheim -- Price Target Raised to $360

Guggenheim has reiterated its Buy rating for Natera (NTRA) and increased its price target from $290 to $360, signaling strong confidence in the company's future. Despite this positive analyst outlook and Natera's high GF Score™ of 77/100, indicating strong growth and momentum, the stock …

Central Garden Pet (CENT) Gets a Sell from J.P. Morgan

Is Concentra Group Holdings Parent (CON) Undervalued Following Strong Earnings And Raised Guidance?

Natera Inc (NTRA) weekly advance accelerates with a 72.8% 12-week climb

The diagnostics stock closed at 322.10 USD as its weekly setup stayed active, with turnover running above its recent average.

Natera partners with Kupando for phase 1 cancer trial in Germany

Natera Inc. has announced a collaboration with Kupando Therapeutics for a Phase 1 clinical trial in Germany for KUP-101, an investigational immunotherapy for advanced tumors. Natera's Latitude tissue-free assay will be used to monitor treatment response by assessing circulating tumor DNA dynamics. The trial …

Concentra Group Holdings Parent, Inc. Stock 12‑Month Price Target Raised to $39.12, Implies 18% Upside

The average 12-month price target for Concentra Group Holdings Parent, Inc. stock has been raised from $38.62 to $39.12 by 8 analysts, with a range of $34 to $42. This new target implies an 18% potential upside based on the Aug. 11 closing price. …

HC Wainwright Analysts Lower Earnings Estimates for TRDA

HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Entrada Therapeutics (NASDAQ:TRDA) to a loss of $1.18, maintaining a "Neutral" rating. The company's recent quarterly results missed expectations, reporting a $1.01 loss per share against an anticipated $0.97 loss, and …

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics' investigational immunotherapy using Latitude MRD testing AUSTIN, Texas, August 12, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a …

First Patient Dosed as Trial Tests Immunotherapy in Skin Cancers

Natera, a leader in cell-free DNA, is collaborating with Kupando Therapeutics on a Phase 1 clinical trial for KUP-101, an immunotherapy for advanced skin cancers. Natera's Latitude MRD test will monitor treatment response by assessing ctDNA dynamics. The first patient has been dosed, and …

Dimensional Fund Advisors LP Has $6.16 Million Stock Position in Entravision Communications Corporation $EVC

Central Garden & Pet Co (CENTA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Entravision Communications Corp (EVC) Stock News Today

Central Puerto (NYSE:CEPU) Announces Earnings Results

Central Puerto (NYSE:CEPU) reported quarterly earnings per share of $0.58, with a net margin of 37.86% and a return on equity of 15.93%. However, the company's revenue of $0.47 million significantly missed the consensus estimate of $204.91 million, leading to a $0.47 drop in …

Central Garden & Pet (CENT) investor files to sell 5,000 Class A shares

A holder of Central Garden & Pet Company Class A Common Stock has filed a Form 144 notice to sell 5,000 shares through Charles Schwab & Co., Inc. The proposed sale is valued at $192,500.00 and is related to prior equity compensation activity, including …

Central Garden & Pet (CENT) chair shifts voting control on family trust shares

Central Garden & Pet (CENT) chairman, William E. Brown, reported indirect dispositions of Class A Common Stock due to changes in family trust control. He and his spouse ceased being co-trustees for two irrevocable trusts, impacting a total of 20,117 shares by removing their …

A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It

Natera's CFO, Michael Burkes Brophy, sold 795 shares worth $216,000 just before the company reported a 38% revenue surge. This transaction was not a discretionary sale but a non-discretionary "sell-to-cover" to meet tax obligations from vested equity awards under a Rule 10b5-1 trading plan. …

Central Bancompany (CBC) Q2 2026 Earnings Call

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 10:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - John RossChief Financial Officer - James CiroliChief Customer Officer - Dan WesthuesChief Credit Officer - Eric Hallgren TAKEAWAYS Net Income -- $113.8 …

Entravision Communications (NYSE:EVC) Shares Gap Down - Should You Sell?

NTRA Q2 Deep Dive: Oncology Milestones and New Product Launches Drive Growth

NTRA Q2 Deep Dive: Oncology Milestones and New Product Launches Drive Growth Genetic testing company Natera (NASDAQ:NTRA) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 37.7% year on year to $752.8 million. The company's full-year revenue guidance of $2.88 …

RingCentral to Present at Oppenheimer Technology, Internet & Communications Conference

BELMONT, Calif., August 11, 2026--(BUSINESS WIRE)--RingCentral, Inc. (NYSE: RNG), a global leader in AI-powered customer engagement, today announced that members of its management team are scheduled to present at the following investor conference: Oppenheimer 29th Annual Technology, Internet & Communications Conference Date: Wednesday, August …

Entravision Communications Corporation Announces Quarterly Dividend of $0.05 (NYSE:EVC)

ADENTRA Inc. ADEN Earnings Beat Estimates by 37.1%

Central Asia Metals (LON:CAML) Given Sector perform Rating at Royal Bank Of Canada

5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620

5AM Ventures V sold 62,811 common shares of Entrada Therapeutics on August 6-7, 2026, for a total value of $431,620. Following these sales, their direct stake in the company decreased to 2,783,781 shares, while 5AM Opportunities I held an indirect stake of 1,093,313 shares.

Concentra Group Holdings Parent (CON) Is Up 7.6% After Raising 2026 Guidance And Detailing CEO Succession – Has The Bull Case Changed?

Concentra Group Holdings Parent (CON) recently reported strong Q2 2026 results, raising full-year guidance and reaffirming its dividend. The company also announced a CEO succession plan, with current President and CFO Matt DiCanio set to take over in November 2026. This positive news, coupled …

Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know

Natera co-founder Matthew Rabinowitz sold 731 shares to cover tax obligations from vested restricted stock units, an action dictated by a pre-established plan rather than a discretionary investment decision. This sale represents a negligible fraction of his substantial holdings, valued at over $616 million. …

Entravision Communications Q2 Earnings Call Highlights

Entravision Communications Corporation Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Consolidated …

Kush Parmar Sells 92,444 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock